Top Pharma Companies in India by Market Cap

Pursuant to Regulation 30 read with Schedule III of the Listing Regulations, RPG Life Sciences has informed that the Board of Directors of the Company, at its meeting held today, Monday, December 15, 2025, considered and unanimously approved the following: 1. Appointment of Amol Lone as the Chief Financial Officer and Key Managerial Personnel (KMP) of the Company effective from December 15, 2025, based on the recommendation of the Nomination and Remuneration Committee of the Company. 2. Incorporation of a new wholly owned subsidiary (‘WOS’) of the Company, in the name and style ‘RPG Active Pharma’ or such other name, as may be approved by the Ministry of Corporate Affairs, to be engaged, in the business of manufacture and marketing of active pharmaceutical ingredients (‘API’) and related pharmaceutical products. 3. Transfer of the API business of the Company to the WOS (upon its incorporation), as a going concern, pursuant to a business transfer agreement, and subject to receipt of applicable statutory and regulatory approvals. 4. Investment of an amount of up to Rs.105 crore in the WOS, in one or more tranches, for the purpose of capitalization, business operations and/or other related requirements. Necessary disclosures as required under the Listing Regulations read with applicable SEBI circulars shall be made as and when further investment is made in the WOS. The detailed disclosures as required under Regulation 30 read with Schedule III of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (‘SEBI Master Circular’), in respect of aforesaid matters are enclosed as Annexures I, II and III, respectively. The meeting commenced at 02:00 pm and concluded at 3.10 pm.

Shilpa Medicare has informed that Shilpa Medicare, headquartered at Raichur, Karnataka, India, has received the Initial Authorization from Europe, recommending the grant of the final Marketing Authorization for Shilpa Medicare’s prescription product, Rotigotine 1, 2, 3, 4, 6, 8 mg/24 h transdermal patch. This application, submitted as a generic application via Decentralized Procedure in Europe and is a generic version of the innovator product Neupro. Shilpa’s product is pharmaceutical and bioequivalent version of the reference product Neupro. Shilpa’s Rotigotine patches are indicated for treatment of Restless Legs Syndrome and Parkinson’s disease. The total addressable European market for Rotigotine is estimated at ~USD 222 million. Shilpa has on boarded a strategic commercialization partner in Europe, with a targeted launch in FY27. 

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Akums Drugs and Pharmaceuticals has informed that the Company is hosting Plant visit for Investors / Financial Institutions on Friday, December 12, 2025 at Haridwar (Manufacturing Facilities). No unpublished price sensitive information pertaining to the Company will be shared at any meet with Investors / Financial Institutions. A copy of this disclosure is being updated on website of the Company at www.akums.in. 

The above information is a part of company’s filings submitted to BSE.